Inflammatory beast cancer by Vassallo, Pierre
inflammatory breast cancer (IBC) is a rare subtype of breast cancer that accounts for 2–5% of all breast cancers. It has a highly virulent course with a low 5-year survival rate of 
25–50%. Standard treatment with preoperative chemotherapy, 
mastectomy, and radiation therapy has been shown to improve 
prognosis.
IBC usually presents with rapid onset of clinical signs that 
develop within 3 months which include breast erythema and 
edema, often with no palpable mass,and may involve one-third 
or more of the breast (Fig 1). Peau d’orange (french for “orange 
skin”) may also be present where the skin is pitted and dimpled 
due to the presence of tumor emboli that obstruct the dermal 
lymphatics (Fig 2). The breast may be enlarged, warm, and 
tender. These symptoms may mimic inflammation, however 
there is no true inflammatory component to IBC. 20–40% of 
patients will already have distant metastases, which reflects the 
very aggressive nature of IBC.
The major differential diagnosis for IBC is breast infection 
(mastitis) with or without an abscess. Mastitis often manifests as 
cutaneous erythema, edema with skin thickening and fever. If a 
focal lump or skin fluctuance is seen, ultrasonography (US) will 
determine whether an abscess is present (Fig 3) and would also 
guide percutaneous drainage. Antibiotic treatment should result 
in complete resolution of the infection. If there is no response 
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Figure 1: Breast erythema and oedema are seen in IBC,  
however there is no palpable mass
Figure 2: Peau d’orange appearance of the skin in IBC
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or an incomplete response to antibiotic treatment within 1–2 
weeks, malignancy such as IBC should be considered. Breast 
abscess formation presents as a ring enhancing lesion on MRI 
with adjacent skin thickening (Fig 4).
Locally advanced breast cancer (LABC) may also present 
with a similar clinical picture, however the onset of IBC occurs 
within a short period (usually 3 months) whereas that of LABC 
is more protracted. Erythema and skin induration (and peau 
d’orange) are less common, but may be present if skin infiltration 
by tumor cells occurs. Mammography of LABC will show a 
large mass (Fig 5) that may have been present clinically for a 
long time, while ultrasound shows a solid hypoechoic mass (Fig 
6). Attempts at aspiration show no pus or fluid and histologic 
diagnosis is established by US-guided core biopsy. Skin punch 
biopsy is utilized to confirm cancerous infiltration of the skin, 
which is a feature of IBC. 
LABC occurs in an older age group and has a better 
prognosis than IBC since it is less aggressive and grows more 
slowly. In LABC, the incidence of distant metastases is lower 
(10% in LABC vs 20-40% in IBC) and its genetic subtypes are 
more likely to respond to therapy; LABC is more likely to be 
Figure 3: Breast abscess 
appearing as a hypoechoic 
area on ultrasound with 
ill-defined margins; 
needle aspiration obtained 
pus from this area, which 
helped diminish bacterial 
load and also provided 
a sample for bacterial 
culture and sensitivity 
studies
Figure 6: US image shows a 7cm 
hypoechoic mass which on US-guided 
core biopsy demonstrated high-grade 
invasive ductal carcinoma
Figure 7: More common 
mammographic presentation 
of IBC with diffuse breast 
enlargement, diffuse increased 
density (arrowhead), skin 
thickening (black arrow), and 
enlarged axillary lymph nodes 
(white arrow)
Figure 4: Breast MRI 
showing a breast abscess 
with rim enhancement 
(arrow) and adjacent skin 
thickening (*)
Figure 5: Mammogram 
showing a 7cm mass 
(arrow) in the upper inner 
breast
oestrogen-receptor (ER) positive and less likely to be HER2 
negative, while IBC has a high incidence of triple-negative 
cancers (50%) and is more frequently HER2 positive (40%). 
Functioning tumor suppressor gene (p53 gene) is lower in IBC 
and multiple genetic factors that stimulate tumor growth are 
more likely to be present.  
In the imaging workup of IBC, mammography is usually 
the initial study that shows diffuse enlargement of the breast 
with diffusely increased density, skin thickening and possibly 
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Figure 12: Dynamic contrast-enhanced MR kinetic studies: (a) Before treatment, 
areas of washout (red) and plateau or persistent enhancement (blue) are seen; 
washout kinetics are strongly indicative of cancer, while persistent or plateau 
kinetics are equivocal, (b) After treatment, there is no contrast enhancement, 
indicating complete response
enlarged lymph nodes (Fig 7). A less common mammographic 
presentation of IBC is that of multiple masses (Fig 8). US can 
help differentiate a benign cystic mass from a solid mass and 
can evaluate a solid mass according to its margins (smooth, 
irregular, or speculated), its size and extent (Fig 9).
If no mass lesion is detected on mammography or US, 
Magnetic Resonance Imaging (MRI) may be used to target 
biopsy as it has been shown to be the most accurate imaging 
technique for detection of the primary breast lesion in patients 
with IBC (Fig 10). The primary breast lesion is detected at 
mammography in 68–80% of cases, at US in 94–95% of cases, 
and at MRI imaging in 98–100% of cases. The more common 
Figure 9: US image of 
IBC shows a 2.7cm, 
irregular, hypoechoic 
mass with posterior 
shadowing
Figure 10: MR shows 
primary breast lesion in 
a patient with IBC, who 
had no detectible lesion 
on mammography and 
initial ultrasound
Figure 11: Most 
common MR 
presentation of IBC 
includes extensive non-
mass-like enhancement 
(arrow) and skin 
thickening (arrowhead)
Figure 8: Less commonly 
IBC may present with 
multiple large masses 
(arrows) on mammography
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appearance of IBC on MRI is however as a diffuse contrast 
enhancing area involving a large part of the breast, with skin 
thickening (Fig 11); presentation as a mass-lesion is less common 
on MRI. Involvement of the pectoralis major muscle and axillary, 
supraclavicular and internal mammary lymph nodes as well as 
the contra-lateral breast are common in IBC and are also best 
assessed with MRI. Evaluation for distant metastatic disease from 
IBC would require Computed Tomography (CT), MRI or [18F]-
fluorodeoxyglucose (FDG) Positron Emission Tomography-
Computed Tomography (FDG PET/CT).
Follow-up imaging during and after treatment may include 
mammography, US and MRI. Dynamic contrast-enhanced MRI 
kinetics are particularly useful for detecting tumor response  
(Fig 12). 
Imaging is vital for the diagnosis and treatment planning 
for patients with IBC. The role of various imaging modalities in 
diagnosis, assessment of treatment response, and surveillance has 
been presented here.  
30
